



The Drug Rediscovery Protocol (DRUP Trial): A Dutch national study on behalf of the CPCT to facilitate patient access to commercially available, targeted anti-cancer drugs to determine the potential efficacy in treatment of advanced cancers with a known molecular profile

# MONTHLY NEWSLETTER #84


April 2023

## DRUP-study update

To date, 2548 cases have been submitted to the DRUP study, of which 1364 (54%) have been started a treatment (see Table 1 below).



*Hello everyone, my name is Marion Bleijendaal, clinical trial assistant since 2008 and allocated to the DRUP study as of March 2023.*



*My role is supporting my colleagues by performing administrative tasks such as creating minutes, updating overviews and document archiving. I am happy to be part of this amazing team and contribute to this very exciting study.*

## Waivers

As we received requests for waivers, we would like to highlight the fact that waivers are only granted in highly exceptional occasions. If it is already evident at submission that a waiver is likely to be required for participation (for example, for the pre-treatment biopsy, comorbidity or lab values), the study team requests that you make this known at the time of submission. That way, the team can include the request in the considerations about participation.

## Study team update

We have welcomed two new members to the team, who will briefly introduce themselves:



*Hi everyone, my name is Emilie van der Sande, and I am the new clinical project manager for both the DRUP and the DAP-study working from NKI-AvL. I have studied bio-pharmaceutical sciences at Leiden University. Recently, I have finished my PhD research in Ophthalmology and Epidemiology, and I will defend this upcoming May at ErasmusMC. I am looking forward to implement my experiences in research, and my background in bio-pharmaceutical sciences in my new job, and thereby contribute to the DRUP-study!*

**Best regards,**

*Principal Investigators:* Henk Verheul, Hans Gelderblom, Emile Voest

*Study Coordinators:* Laurien Zeverijn, Birgit Geurts, Ilse Spiekman, Karlijn Verkerk, Georgy Gomon, Soemeya Haj Mohammad

*Clinical Trial Assistant:* Marion Bleijendaal

*Clinical Project Manager:* Emilie van der Sande

<b>Table 1: List of pharmaceutical companies &amp; study drugs</b>			
Confidential, list might be subjected to changes			
<b>Currently available</b>			
<u>Amgen</u>	<u>Eisai</u>	<u>MSD</u>	<u>Roche</u>
Panitumumab	Lenvatinib	Pembrolizumab	Erlotinib
			Trastuzumab+
			Pertuzumab
<u>BMS</u>	<u>AstraZeneca</u>	<u>Lilly</u>	Vemurafenib+
Nivolumab	Olaparib	Abemaciclib	Cobimetinib
Ipilimumab	Durvalumab	Selpercatinib	Vismodegib
			Atezolizumab+
<u>Novartis</u>	<u>Pfizer</u>	<u>Janssen</u>	bevacizumab
Dabrafenib	Axitinib	Erdafitinib	Alectinib
Nilotinib	Crizotinib		Entrectinib
Trametinib	Sunitinib		
Alpelisib	Talazoparib		
	Dacomitinib		
	Lorlatinib		
<b>Committed</b>			
<u>GSK</u>	<u>Merck</u>		
Niraparib	Tepotinib		

<b>Calendar &amp; publicity</b>
IDMC meeting 30 <sup>th</sup> May, 2023

